FDA Approves Sacituzumab Govitecan-Hziy for First-Line Metastatic Triple-Negative Breast Cancer Treatment

The U.S. Food and Drug Administration (FDA) has approved sacituzumab govitecan-hziy (Trodelvy) for first-line treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC), according to an announcement from the agency on June 25, 2024. This marks the first FDA approval for a targeted therapy in this setting, offering a new standard for patients with limited treatment options.

Sacituzumab govitecan-hziy, developed by Immunomedics, Inc. (now part of Gilead Sciences), is an antibody-drug conjugate (ADC) designed to deliver a cytotoxic payload directly to cancer cells expressing the Trop-2 protein, which is highly expressed in TNBC. The approval follows results from the Phase 3 TROPiCS-02 trial, published in The New England Journal of Medicine in 2023, showing a 40% reduction in the risk of disease progression or death compared to chemotherapy alone.

Why this approval matters
Triple-negative breast cancer accounts for about 10–15% of all breast cancer cases but carries a disproportionately high mortality rate due to its aggressive nature and lack of targeted therapies. Historically, standard first-line treatment has relied on chemotherapy, which offers limited durability. The FDA’s decision reflects a shift toward precision medicine in TNBC, where sacituzumab govitecan-hziy’s mechanism—targeting Trop-2—has demonstrated improved outcomes in clinical trials.

Key details of the approval
The FDA’s accelerated approval was based on data from the TROPiCS-02 trial, which enrolled 543 patients with previously untreated metastatic TNBC. Patients treated with sacituzumab govitecan-hziy showed a median progression-free survival (PFS) of 9.9 months compared to 6.9 months for those receiving chemotherapy (paclitaxel or nab-paclitaxel). The overall response rate was 53% in the ADC group versus 36% in the chemotherapy group.

The drug’s label includes a boxed warning for severe myelosuppression, diarrhea, and interstitial lung disease, reflecting its safety profile observed in clinical trials. The recommended dose is 10 mg/kg administered intravenously on days 1 and 8 of a 21-day cycle. Gilead Sciences has stated it will make the drug available immediately, though pricing has not yet been disclosed.

How it compares to existing treatments
Prior to this approval, TNBC patients had few targeted options beyond chemotherapy and immunotherapy (e.g., atezolizumab in combination with nab-paclitaxel). Sacituzumab govitecan-hziy’s approval expands the first-line arsenal but does not replace existing standards. The American Society of Clinical Oncology (ASCO) has noted that while the drug improves PFS, its long-term survival benefit and quality-of-life impact require further study.

What comes next
The FDA’s approval is based on ongoing confirmation trials, a requirement for accelerated approvals. Gilead Sciences has committed to submitting confirmatory data within the next 18 months. Meanwhile, oncologists and patient advocacy groups are assessing how sacituzumab govitecan-hziy will integrate into clinical practice, particularly for patients who may not tolerate chemotherapy or whose tumors progress despite immunotherapy.

Uncertainties and ongoing research
While the approval is a milestone, questions remain about the drug’s cost-effectiveness and accessibility. The National Comprehensive Cancer Network (NCCN) has emphasized the need for real-world evidence to clarify its role in diverse patient populations. Additionally, research into Trop-2 expression variability and resistance mechanisms is ongoing, as observed in earlier ADC trials.